BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26887378)

  • 1. Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy.
    Yokota T; Tachibana H; Konishi T; Yurikusa T; Hamauchi S; Sakai K; Nishikawa M; Suzuki M; Naganawa Y; Hagihara T; Tsumaki H; Kubo T; Sato M; Taguri M; Morita S; Eguchi T; Kubota K; Zenda S
    Support Care Cancer; 2016 Jul; 24(7):3029-36. PubMed ID: 26887378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer.
    Yokota T; Hamauchi S; Yoshida Y; Yurikusa T; Suzuki M; Yamashita A; Ogawa H; Onoe T; Mori K; Onitsuka T
    Support Care Cancer; 2018 Sep; 26(9):3241-3248. PubMed ID: 29627862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Yokota T; Ogawa T; Takahashi S; Okami K; Fujii T; Tanaka K; Iwae S; Ota I; Ueda T; Monden N; Matsuura K; Kojima H; Ueda S; Sasaki K; Fujimoto Y; Hasegawa Y; Beppu T; Nishimori H; Hirano S; Naka Y; Matsushima Y; Fujii M; Tahara M
    BMC Cancer; 2017 May; 17(1):314. PubMed ID: 28476132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer.
    Chung YL; Pui NNM
    Support Care Cancer; 2017 Sep; 25(9):2743-2751. PubMed ID: 28353040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
    Yen SH; Wang LW; Lin YH; Jen YM; Chung YL
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1463-70. PubMed ID: 21840136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.
    Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M
    J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial.
    Legouté F; Bensadoun RJ; Seegers V; Pointreau Y; Caron D; Lang P; Prévost A; Martin L; Schick U; Morvant B; Capitain O; Calais G; Jadaud E
    Radiat Oncol; 2019 May; 14(1):83. PubMed ID: 31118057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the Risk Factors for Severe Oral Mucositis in Head and Neck Cancer after Chemoradiotherapy with S-1].
    Nagatani A; Ogawa Y; Sunaga T; Tomura K; Naito Y; Fujii N; Okabe T; Hashimoto T; Kogo M; Sasaki T
    Yakugaku Zasshi; 2017; 137(2):221-225. PubMed ID: 28154335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of Zataria extract mouthwash for the management of radiation-induced oral mucositis in patients: a randomized placebo-controlled double-blind study.
    Aghamohammadi A; Moslemi D; Akbari J; Ghasemi A; Azadbakht M; Asgharpour A; Hosseinimehr SJ
    Clin Oral Investig; 2018 Jul; 22(6):2263-2272. PubMed ID: 29313134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between cumulative radiation dose and the incidence of severe oral mucositis in head and neck cancers during radiotherapy.
    Sunaga T; Nagatani A; Fujii N; Hashimoto T; Watanabe T; Sasaki T
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1317. PubMed ID: 33295153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of photobiomodulation on the severity of oral mucositis and molecular changes in head and neck cancer patients undergoing radiotherapy: a study protocol for a cost-effectiveness randomized clinical trial.
    Martins AFL; Nogueira TE; Morais MO; Oton-Leite AF; Valadares MC; Batista AC; Freitas NMA; Leles CR; Mendonça EF
    Trials; 2019 Feb; 20(1):97. PubMed ID: 30709370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy--a randomized controlled trial.
    Gautam AP; Fernandes DJ; Vidyasagar MS; Maiya AG; Nigudgi S
    Support Care Cancer; 2013 May; 21(5):1421-8. PubMed ID: 23224689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy.
    Rastogi M; Khurana R; Revannasiddaiah S; Jaiswal I; Nanda SS; Gupta P; Chufal KS; Bhatt ML
    Support Care Cancer; 2017 May; 25(5):1439-1443. PubMed ID: 27987094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer.
    Giralt J; Tao Y; Kortmann RD; Zasadny X; Contreras-Martinez J; Ceruse P; Arias de la Vega F; Lalla RV; Ozsahin EM; Pajkos G; Mazar A; Attali P; Bossi P; Vasseur B; Sonis S; Henke M; Bensadoun RJ
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):320-328. PubMed ID: 31669562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy.
    Trotti A; Garden A; Warde P; Symonds P; Langer C; Redman R; Pajak TF; Fleming TR; Henke M; Bourhis J; Rosenthal DI; Junor E; Cmelak A; Sheehan F; Pulliam J; Devitt-Risse P; Fuchs H; Chambers M; O'Sullivan B; Ang KK
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):674-81. PubMed ID: 14967419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer.
    Ueno T; Zenda S; Konishi T; Yurikusa T; Shibasaki Y; Nagamoto H; Fujii M
    Int J Clin Oncol; 2019 Mar; 24(3):241-247. PubMed ID: 30426268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of polyacrylate silver salt/polyvinylpyrrolidone-based liquid oral gel in management of concurrence chemoradiotherapy-induced oral mucositis.
    Chin HL; Chung KP; Liu HC; Chen RS; Chang HH; Chen MH
    J Formos Med Assoc; 2023 Aug; 122(8):723-730. PubMed ID: 36623972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
    Gouvêa de Lima A; Villar RC; de Castro G; Antequera R; Gil E; Rosalmeida MC; Federico MH; Snitcovsky IM
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):270-5. PubMed ID: 21163585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Young head and neck cancer patients are at increased risk of developing oral mucositis and trismus.
    Morais-Faria K; Palmier NR; de Lima Correia J; de Castro Júnior G; Dias RB; da Graça Pinto H; Lopes MA; Ribeiro ACP; Brandão TB; Santos-Silva AR
    Support Care Cancer; 2020 Sep; 28(9):4345-4352. PubMed ID: 31912359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RRM1 gene expression evaluated in the liquid biopsy (blood cfRNA) as a non-invasive, predictive factor for radiotherapy-induced oral mucositis and potential prognostic biomarker in head and neck cancer patients.
    Mlak R; Powrózek T; Brzozowska A; Homa-Mlak I; Mazurek M; Małecka-Massalska T
    Cancer Biomark; 2018; 22(4):657-667. PubMed ID: 29865035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.